Loading…

Memory modulation with peripherally acting cholinergic drugs

Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize th...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacologia 1992-03, Vol.106 (3), p.375-382
Main Authors: RUSH, D. K, STREIT, K
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343
cites cdi_FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343
container_end_page 382
container_issue 3
container_start_page 375
container_title Psychopharmacologia
container_volume 106
creator RUSH, D. K
STREIT, K
description Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg. The NEO antagonism of the SCOP amnesia could be reversed with SCOP (0.3, 1, and 3 mg/kg) and mecamylamine (MECA, 1, 3, and 10 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active both peripherally and centrally, as well as with M-SCOP (0.3 and 1 mg/kg) and hexamethonium (HEX, 1 and 3 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active only in the periphery. In contrast to the ability of these four compounds to attenuate the SCOP amnesia, only the centrally acting compounds SCOP (3 mg/kg) and MECA (10 mg/kg) induced an amnesia when administered alone. These findings suggest that the induction of amnesia of passive avoidance involves central cholinergic systems, whereas the NEO, and possibly PHYSO, reversal of the SCOP induced amnesia is mediated peripherally by both muscarinic and nicotinic receptors. It is hypothesized that the release of adrenal catecholamines, the influence of which on memory processes is well known, and secondarily glucose, may be responsible for the NEO antagonism of the SCOP amnesia.
doi_str_mv 10.1007/BF02245421
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF02245421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1570386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343</originalsourceid><addsrcrecordid>eNpFkE1LAzEYhIMotVYv3oU9eBJW3-TNxy54scWqUPGi5yWbTdrIfpHsIv33VlrsXOYwDwMzhFxTuKcA6mG-BMa44IyekCnlyFIGip2SKQBiilRk5-Qixm_YiWd8QiZUKMBMTsnju226sE2arhprPfiuTX78sEl6G3y_sUHX9TbRZvDtOjGbrvatDWtvkiqM63hJzpyuo706-Ix8LZ8_F6_p6uPlbfG0Sg1SOqTMKW1VxsrKSlcBijwvNZSomVDGKioclVI4xSUHkRtjHC8ZVzKX2pUZcpyRu32vCV2MwbqiD77RYVtQKP4eKI4P7OCbPdyPZWOrI7qfvMtvD7mORtcu6Nb4-I8JgQoFx1-WiGJE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Memory modulation with peripherally acting cholinergic drugs</title><source>Springer Online Journal Archives</source><creator>RUSH, D. K ; STREIT, K</creator><creatorcontrib>RUSH, D. K ; STREIT, K</creatorcontrib><description>Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg. The NEO antagonism of the SCOP amnesia could be reversed with SCOP (0.3, 1, and 3 mg/kg) and mecamylamine (MECA, 1, 3, and 10 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active both peripherally and centrally, as well as with M-SCOP (0.3 and 1 mg/kg) and hexamethonium (HEX, 1 and 3 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active only in the periphery. In contrast to the ability of these four compounds to attenuate the SCOP amnesia, only the centrally acting compounds SCOP (3 mg/kg) and MECA (10 mg/kg) induced an amnesia when administered alone. These findings suggest that the induction of amnesia of passive avoidance involves central cholinergic systems, whereas the NEO, and possibly PHYSO, reversal of the SCOP induced amnesia is mediated peripherally by both muscarinic and nicotinic receptors. It is hypothesized that the release of adrenal catecholamines, the influence of which on memory processes is well known, and secondarily glucose, may be responsible for the NEO antagonism of the SCOP amnesia.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/BF02245421</identifier><identifier>PMID: 1570386</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Amnesia - chemically induced ; Amnesia - psychology ; Animals ; Behavior, Animal - drug effects ; Biological and medical sciences ; Ganglionic Stimulants - antagonists &amp; inhibitors ; Male ; Medical sciences ; Memory - drug effects ; Mice ; Neostigmine - pharmacology ; Neuropharmacology ; Parasympatholytics - pharmacology ; Parasympathomimetics - pharmacology ; Pharmacology. Drug treatments ; Physostigmine - pharmacology ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Scopolamine - antagonists &amp; inhibitors ; Scopolamine - pharmacology</subject><ispartof>Psychopharmacologia, 1992-03, Vol.106 (3), p.375-382</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343</citedby><cites>FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5537354$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1570386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RUSH, D. K</creatorcontrib><creatorcontrib>STREIT, K</creatorcontrib><title>Memory modulation with peripherally acting cholinergic drugs</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology (Berl)</addtitle><description>Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg. The NEO antagonism of the SCOP amnesia could be reversed with SCOP (0.3, 1, and 3 mg/kg) and mecamylamine (MECA, 1, 3, and 10 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active both peripherally and centrally, as well as with M-SCOP (0.3 and 1 mg/kg) and hexamethonium (HEX, 1 and 3 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active only in the periphery. In contrast to the ability of these four compounds to attenuate the SCOP amnesia, only the centrally acting compounds SCOP (3 mg/kg) and MECA (10 mg/kg) induced an amnesia when administered alone. These findings suggest that the induction of amnesia of passive avoidance involves central cholinergic systems, whereas the NEO, and possibly PHYSO, reversal of the SCOP induced amnesia is mediated peripherally by both muscarinic and nicotinic receptors. It is hypothesized that the release of adrenal catecholamines, the influence of which on memory processes is well known, and secondarily glucose, may be responsible for the NEO antagonism of the SCOP amnesia.</description><subject>Amnesia - chemically induced</subject><subject>Amnesia - psychology</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Ganglionic Stimulants - antagonists &amp; inhibitors</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Memory - drug effects</subject><subject>Mice</subject><subject>Neostigmine - pharmacology</subject><subject>Neuropharmacology</subject><subject>Parasympatholytics - pharmacology</subject><subject>Parasympathomimetics - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Physostigmine - pharmacology</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Scopolamine - antagonists &amp; inhibitors</subject><subject>Scopolamine - pharmacology</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNpFkE1LAzEYhIMotVYv3oU9eBJW3-TNxy54scWqUPGi5yWbTdrIfpHsIv33VlrsXOYwDwMzhFxTuKcA6mG-BMa44IyekCnlyFIGip2SKQBiilRk5-Qixm_YiWd8QiZUKMBMTsnju226sE2arhprPfiuTX78sEl6G3y_sUHX9TbRZvDtOjGbrvatDWtvkiqM63hJzpyuo706-Ix8LZ8_F6_p6uPlbfG0Sg1SOqTMKW1VxsrKSlcBijwvNZSomVDGKioclVI4xSUHkRtjHC8ZVzKX2pUZcpyRu32vCV2MwbqiD77RYVtQKP4eKI4P7OCbPdyPZWOrI7qfvMtvD7mORtcu6Nb4-I8JgQoFx1-WiGJE</recordid><startdate>19920301</startdate><enddate>19920301</enddate><creator>RUSH, D. K</creator><creator>STREIT, K</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920301</creationdate><title>Memory modulation with peripherally acting cholinergic drugs</title><author>RUSH, D. K ; STREIT, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Amnesia - chemically induced</topic><topic>Amnesia - psychology</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Ganglionic Stimulants - antagonists &amp; inhibitors</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Memory - drug effects</topic><topic>Mice</topic><topic>Neostigmine - pharmacology</topic><topic>Neuropharmacology</topic><topic>Parasympatholytics - pharmacology</topic><topic>Parasympathomimetics - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Physostigmine - pharmacology</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Scopolamine - antagonists &amp; inhibitors</topic><topic>Scopolamine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RUSH, D. K</creatorcontrib><creatorcontrib>STREIT, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RUSH, D. K</au><au>STREIT, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Memory modulation with peripherally acting cholinergic drugs</atitle><jtitle>Psychopharmacologia</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>1992-03-01</date><risdate>1992</risdate><volume>106</volume><issue>3</issue><spage>375</spage><epage>382</epage><pages>375-382</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>Physostigmine (PHYSO), in doses as low as 0.003 mg/kg IP, antagonized scopolamine (SCOP, 3 mg/kg) induced amnesia of step-through passive avoidance in mice. The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg. The NEO antagonism of the SCOP amnesia could be reversed with SCOP (0.3, 1, and 3 mg/kg) and mecamylamine (MECA, 1, 3, and 10 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active both peripherally and centrally, as well as with M-SCOP (0.3 and 1 mg/kg) and hexamethonium (HEX, 1 and 3 mg/kg), muscarinic and nicotinic antagonists, respectively, which are active only in the periphery. In contrast to the ability of these four compounds to attenuate the SCOP amnesia, only the centrally acting compounds SCOP (3 mg/kg) and MECA (10 mg/kg) induced an amnesia when administered alone. These findings suggest that the induction of amnesia of passive avoidance involves central cholinergic systems, whereas the NEO, and possibly PHYSO, reversal of the SCOP induced amnesia is mediated peripherally by both muscarinic and nicotinic receptors. It is hypothesized that the release of adrenal catecholamines, the influence of which on memory processes is well known, and secondarily glucose, may be responsible for the NEO antagonism of the SCOP amnesia.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>1570386</pmid><doi>10.1007/BF02245421</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacologia, 1992-03, Vol.106 (3), p.375-382
issn 0033-3158
1432-2072
language eng
recordid cdi_crossref_primary_10_1007_BF02245421
source Springer Online Journal Archives
subjects Amnesia - chemically induced
Amnesia - psychology
Animals
Behavior, Animal - drug effects
Biological and medical sciences
Ganglionic Stimulants - antagonists & inhibitors
Male
Medical sciences
Memory - drug effects
Mice
Neostigmine - pharmacology
Neuropharmacology
Parasympatholytics - pharmacology
Parasympathomimetics - pharmacology
Pharmacology. Drug treatments
Physostigmine - pharmacology
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Scopolamine - antagonists & inhibitors
Scopolamine - pharmacology
title Memory modulation with peripherally acting cholinergic drugs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T01%3A01%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Memory%20modulation%20with%20peripherally%20acting%20cholinergic%20drugs&rft.jtitle=Psychopharmacologia&rft.au=RUSH,%20D.%20K&rft.date=1992-03-01&rft.volume=106&rft.issue=3&rft.spage=375&rft.epage=382&rft.pages=375-382&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/BF02245421&rft_dat=%3Cpubmed_cross%3E1570386%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-2f7ae782bde6fd03599ba0b3a257ce715f1665f7464059cccf4b247696afb8343%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/1570386&rfr_iscdi=true